Trial · NCT03446885
Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD
NCT03446885, Phase 4, Completed, Gregory Fabiano; results first posted 2021-06-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD. Trials, record NCT03446885. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03446885
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD
- NCT number
- NCT03446885
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 22 participants, actual
- Lead sponsor
- Gregory Fabiano
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Lisdexamfetamine Dimesylate 40 MG, Placebo
- First posted
- 2018-02-27
- Last updated
- 2021-06-24
- Results first posted
- 2021-06-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ratings of Job Application Quality | during interventional study session, 1 day in duration | Three independent coders will review each de-identified application. Following the review of the application, coders will complete a rating form that asks them to make an overall evaluation regarding whether the person was an acceptable job candidate for an interview using a scale of 1 ("definitely not") to 5 ("definitely"). Average rating across coders will be used as the dependent measure. |
| Primary | Ratings of Job Interview Performance | during interventional study session, 1 day in duration | Three coders who are unaware of the study participant identities or group status will view the job interview videotape and completed a form. Raters will provide a rating of their overall impression of the interview behavior ranging from a score of one (Poor) to four (Outstanding). The average score of the coders will be utilized as a dependent measure. |
| Primary | Objective Observation of Workplace Productivity | during interventional study session, 1 day in duration | The dependent measures from this aspect of the study are the number of items completed correctly out of the total number of assigned items (i.e., 225). Thus, the score reflects the percentage of items correctly completed out of the 225 assigned and scores could range from 0-100. |
| Primary | Inattentive/Overactive Rating | during interventional study session, 1 day in duration | In addition to ratings of the interview performance, the rater also will complete the five-item inattentive/overactive (I/O) factor of the Iowa Conners rating scale (Atkins, Pelham, \& Licht, 1989; Loney \& Milich, 1982; Pelham, Milich, Murphy, \& Murphy, 1989). The five items are rated on a scale of Not at all (0) to Very Much (3) and the sum of these items represents the score. The dependent measure will be the score averaged across raters. Scores can range from 0-3 on each item, and the average score of the 5 items was used. Higher scores reflect greater inattentive/overactivity-related behaviors. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Ratings of Job Application Quality | during interventional study session, 1 day in duration | score on a scale | MEAN | |
| PRIMARY | Ratings of Job Interview Performance | during interventional study session, 1 day in duration | score on a scale | MEAN | |
| PRIMARY | Objective Observation of Workplace Productivity | during interventional study session, 1 day in duration | score on a scale | MEAN | |
| PRIMARY | Inattentive/Overactive Rating | during interventional study session, 1 day in duration | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ratings of Job Application Quality | Placebo | 3.40 | Standard Deviation 1.03 | score on a scale | |
| Ratings of Job Application Quality | Vyvanse | 3.56 | Standard Deviation 1.00 | score on a scale | |
| Ratings of Job Interview Performance | Placebo | 3.17 | Standard Deviation .76 | score on a scale | |
| Ratings of Job Interview Performance | Vyvanse | 3.33 | Standard Deviation .91 | score on a scale | |
| Objective Observation of Workplace Productivity | Placebo | 65.60 | Standard Deviation 17.55 | score on a scale | |
| Objective Observation of Workplace Productivity | Vyvanse | 68.45 | Standard Deviation 15.60 | score on a scale | |
| Inattentive/Overactive Rating | Placebo | 2.13 | Standard Deviation 1.33 | score on a scale | |
| Inattentive/Overactive Rating | Vyvanse | 2.01 | Standard Deviation 1.28 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Allocated to Vyvanse First | 12 | |
| Overall Study | STARTED | Allocated to Placebo First | 10 | |
| Overall Study | COMPLETED | Allocated to Vyvanse First | 10 | |
| Overall Study | COMPLETED | Allocated to Placebo First | 10 | |
| Overall Study | NOT COMPLETED | Allocated to Vyvanse First | 2 | |
| Overall Study | NOT COMPLETED | Allocated to Placebo First | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 20 |
| Total, all-cause mortality | Vyvanse | 0 | 20 |
| Total, other adverse events | Placebo | 0 | 20 |
| Total, other adverse events | Vyvanse | 0 | 20 |
| Total, serious adverse events | Placebo | 0 | 20 |
| Total, serious adverse events | Vyvanse | 0 | 20 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32297783 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Vyvanse vs Placebo: deaths from any cause | Trial comparisons |
| Vyvanse vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03446885
GET https://conductscience.org/api/trials/v1/NCT03446885/registered